CE on SUNDAY Miami, FL May 31, 2009
|
|
- Lionel Barker
- 5 years ago
- Views:
Transcription
1 CE on SUNDAY Miami, FL May 31, 2009 Date: Sunday, May 31, 2009 Time: 1:15 PM 2:15 PM Location: Doubletree Miami Mart/Airport Hotel Title: Speaker(s): Understanding Diabetes and Insulin Delivery Systems ACPE # L01-P CEU ACPE # L01-T CEU Financially supported by Sanofi-aventis Scott Stolte, Pharm.D., Shenandoah University Learning Objectives: Upon completion of this activity, participants will be able to: 1. List the pharmacological approaches to the management of Type II Diabetes to include their mechanisms of action, comparative efficacy, pharmacokinetics, and contraindications of agents. 2. Compare and contrast the different options for insulin delivery systems. 3. Describe the pharmacist s role in counseling and educating patients on drug treatment strategies, use of insulin delivery systems, and medication adherence to improve the quality of life and long-term maintenance of diabetes. Disclosures: Scott Stolte, Pharm.D., Shenandoah University declares no conflicts of interest or financial interests in any product or service mentioned in this program, including grants, employment, gifts, stock holdings, or honoraria. Speaker(s) Biography: Dr. Scott Stolte joined the faculty of the Bernard J. Dunn School of Pharmacy at Shenandoah University in Scott served as a faculty member and as Chair of the Department of Pharmacy Practice prior to assuming his position as Associate Dean for Academic Affairs. Dr. Stolte earned his Doctor of Pharmacy degree from Purdue University in West Lafayette, IN in After graduation, Dr. Stolte was the initial community pharmacy resident at Family PharmaCare, Inc. and Purdue University. Scott completed the American Association of Colleges of Pharmacy (AACP) Academic Leadership Fellowship program in While maintaining his interest in progressive community pharmacy practice and primary care disease state management, he has expanded his areas of teaching, service, and scholarship to include distance education, educational assessment, experiential education, and the application of leadership skills and traits to pharmacy and academic medicine.
2 Scott K. Stolte, Pharm.D. Associate Dean, Academic Affairs Bernard J. Dunn School of Pharmacy Shenandoah University Winchester, VA This program has been brought to you by Glucose PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Metformin Biguanide Improve insulin sensitivity at the liver (decreases hepatic glucose output) Enhances insulin sensitivity at the peripheral (muscle) tissues Presence of insulin is required Therapeutic Options Biguanides metformin Sulfonylureas Thiazolidinediones rosiglitazone, pioglitazone Glinides repaglitinide, nataglitinide Alpha-glucosidase inhibitors miglitol, acarbose DPP-4 inhibitors sitagliptan Incretin mimetic exenatide Amylin mimetic pramlintide Insulin Metformin UK-PDS Reduced macrovascular complications in obese patients Reduced all-cause mortality and risk of stroke compared to intensive therapy with insulin or a sulfonlyurea Reduced diabetes-related death and MI versus conventional therapy Monotherapy Reduce FBG by mg/dl and HbA1C by % Other effects Increase HDL cholesterol (2%) Decrease triglycerides (16%) and LDL cholesterol (8%) Weight loss (2-5 kg or lbs.) Should be part of therapy for ALL TYPE 2 pts w/o contraindications!!!
3 Metformin - Combination therapy Sulfonylureas Further reduction of 25-30% in FBG and 2.2% in HbA1C Glitazones Further reduction of 0.9% in HbA1C Acarbose/miglitol Further reduction of 0.4% HbA1C Glinides Further reduction of 1.4% HbA1C Sitagliptan Further reduction of 0.7% HbA1C Exenatide Further reduction of 0.8% in HbA1C Insulin Further reduction of 1.7% in HbA1C Sulfonylureas Combination therapy Metformin Glitazones Further reduction of 1.1% in HbA1C Acarbose/miglitol Further reduction in HbA1C of 1.6% Sitagliptan Further reduction in HbA1C of 0.6% Exenatide Further reduction in HbA1C of 0.9% Insulin intermediate or long-acting Further reduction of 1.9% in HbA1C BIDS - Bedtime Insulin Daytime Sulfonylurea Sulfonylureas Insulin secretagogues Enhance insulin secretion from beta-cells Leads to suppression of hepatic glucose production Increase sensitivity of pancreatic beta cells to glucose Second Generation drugs used primarily Glipizide, glyburide, glimepiride Sulfonylureas Positive predictors of response Newly diagnosed Type 2 (no indicators of Type 1) High fasting C-peptide Moderate fasting hyperglycemia (< 250 mg/dl) Extensively metabolized by CYP2C9 CYP2C9 has alleles Sulfonylureas Treatment with equipotent doses of all agents will produce a similar response Dosing Lower doses in elderly and compromised renal or hepatic function Titrate every 1 to 2 wks Monotherapy Reduce FBG by mg/dl and HbA1C by % Primary failure (15-25%) Secondary failure (5-7%/yr) Thiazolidinediones Activate PPARγ (peroxisome proliferator activator receptor γ) on fat and vascular cells Indirectly improves insulin sensitivity at the skeletal muscle and adipose tissue (and possibly the liver) by enhancing insulin action at the receptor and post receptor level Lowers plasma insulin levels Presence of insulin is required
4 Thiazolidinediones Dosing Onset of action is SLOW (2-3 months) Maximum effect may take 3 to 4 months Can titrate after 12 weeks Monotherapy Reduce FBG by mg/dl and HbA1C by % Other effects Pioglitazone: TG (10-20%), LDL, HDL Rosiglitazone: TG, LDL (5-15%), HDL Convert small dense LDL to larger, less atherogenic LDL Glinides Dosing Up to 30 minutes prior to each meal If meal is skipped, do not take medication Titrate weekly Good to use in elderly and in renal impairment Monotherapy Reduce FBG by 20-30% and HbA1C by 0.8-1% of repaglinide > nateglinide Combination Metformin Thiazolidinediones Thiazolidinediones Combination Therapy Metformin Sulfonylureas Glinides Further reduction of 1.7% in HbA1C Sitagliptan Further reduction in HbA1C of 0.9% Exenatide Further reduction of 0.8% in HbA1C Insulin (> 30 units/day) Reduce insulin by 10-25% when FBG < 120 mg/dl Further reduction of 1.2% in HbA1C Alpha-glucosidase inhibitors Competitively inhibits α-glucosidases that break down starches in the small intestine Inhibits the breakdown of oligosaccharides and disaccharides into monosaccharides Delay in carbohydrate absorption and reduction in postprandial glucose levels Glinides Enhance insulin secretion similar to sulfonylureas BUT, require the presence of glucose to stimulate insulin Help restore first-phase insulin secretion Compared to sulfonylureas Increased absorption and shorter half-life Alpha-glucosidase inhibitors Dosing Take with first bite of meal Titrate to patient tolerance Monotherapy Reduce FBG by 0-15 mg/dl, PPBG by mg/dl, and HbA1C by % Postprandial glucose improves more than fasting levels Rarely used as monotherapy Combination Therapy Sulfonylureas Metformin Increase in GI side effects Insulin
5 Colesevelam Bile-acid sequestrant known as Welchol Recently approved for management of Type 2 diabetes Unknown Possible link between bile acid and glucose homeostasis? reduce amount of glucose absorbed Dosing 625mg tablets: 6 tablets daily or 3 tablets twice daily with meal or liquid Sitagliptin Indicated for monotherapy or adjunctive therapy with metformin or thiazolidinediones Reduces FBG by mg/dl, PPBG by mg/dl, and HbA1C by 0.7 to 1% Need more long-term studies Only studied early in the treatment of Type 2 diabetes Colesevelam Indicated for adjunctive therapy with metformin, sulfonylureas or insulin Reduces FBG by mg/dl and HbA1C by 0.3 to 0.5% Reduces LDL by 12-16% Exenatide Incretin mimetic known as Byetta Biosynthetic form of an incretin, GLP-1 (glucagon-like peptide) From the saliva for the gila monster lizard Potentates glucose-dependent insulin secretion by beta cells Suppresses inappropriately elevated glucagon secretion Slows gastric emptying Reduces food intake Restores first-phase response Animal studies: islet neogenesis, beta-cell proliferation, and increased beta-cell mass Sitagliptin Dipeptidyl-peptidase-4 inhibitor known as Januvia Endogenous GLP-1 has a short half-life of < 2 minutes due to rapid inactivation by DPP-4 Block the breakdown of GLP-1 by inhibiting DPP-4 Potentates effects of endogenous GLP-1 Potentates glucose-dependent insulin secretion by beta-cells Suppresses glucagon secretion No to marginal slowing of gastric emptying Animal studies: improves islet survival and maintains beta-cell mass and function Exenatide Approved as adjunctive therapy to metformin, sulfonylureas, or TZDs Reduces FBG by mg/dl, PPBG by 71 mg/dl, and HbA1C by 0.8 to 1.1% Weight reductions of 3.5 to 8 lbs at 1 yr and 11 lbs at 2.5 yrs at maximum dose (weight loss continues with duration of use)
6 Pramlintide Amylin mimetic known as Symlin Slows gastric emptying, suppress glucagon secretion, and reduces appetite Reduces FBG by 28 mg/dl, PPBG by 24 mg/dl, and HbA1C by 0.4 to 0.7%, Weight reductions of 2.6 to 6 lbs Insulin Onset (hrs) Peak (hrs) Duration (hrs) Administration NPH (various) Twice daily* Glargine (Lantus) >24 Every 24 hrs* Detemir Every hrs* (Levemir) *Doses > 90 u/d should be split into 2 injections Detemir may require BID dosing in 33-50% If evidence of detemir or glargine wearing-off consider BID -controlled mid-injection pre-prandial BG and elevated pre-injection pre-prandial BG Insulin Onset Peak Duration Administration Lispro (Humalog) (minutes ) (hrs) 1-2 (hrs) 3-4 Within 10 Aspart minutes of meal (NovaLog) Glulisine (Apidra) Regular (various) min prior to meal Insulin Therapy Formulations Vials Pen devices SC pumps CSII (continuous subcutaneous insulin infusion)
7 Insulin Therapy Vials: drawing up insulin dose Wash hands and sterilize top of insulin vial Use a new syringe and needle every time Draw air into the syringe equal to dosage Inject the air into the vial (do not remove syringe) Draw up dose into syringe Remove air bubbles (while syringe in vial) Tap syringe to get air bubbles to top of syringe Carefully eject air and draw in dose Insulin Delivery Pens Disposable Pens Humulin N, 70/30 Humalog 75/25, 50/50 Humalog Humalog KwikPen Novolin R, N Novolog 70/30 Novolog Levemir Lantus Solostar Kwik Pen (for humalog types of insulin) Reusable Pens HumaPen Memoir HumaPen Luxura HD NovoPen 3 NovoPen 4 NovoPen Junior Opticlik for Lantus and Apidra Insulin Therapy Pens: setting the dose Injecting insulin Determine injection site Clean skin Pinch skin fold Insert needle into skin fold at a 90 o angle Slowly inject the insulin by pushing the plunger or button all of the way Pull needle straight out Do NOT rub the area Discard syringe and/or needle Disposable Insulin pens Lilly Pens Humalog Humalog 75/25 Humalog 50/50 Humulin 70/30 Humulin N Multiple dose device containing 3 ml (300 units) of U-100 insulin Up to 60 units per dose Dialed by single units (can be dialed in the opposite direction if needed to correct dose amount) Disposable Insulin Pens Kwik Pen Prefilled with Humalog types of insulin Same as Lilly pens Lightweight Easy hand position
8 Disposable Insulin Pens Novo Nordisk Pens Reusable Insulin Pens Lilly Pens Novolog Mix 70/30, Novolog, Novo Levemir Contains 3mL (300 units) of insulin, up to 60 units per dose. Dose in 1-unit increments and can be turned backward and forward to adjust dose. Larger dialing window. HumaPen Luxura HD Only for use with Humalog and uses 3mL Cartridges (100IU/mL) Up to 30 units per dose and can be dialed forward or backward for adjusting dose. ½ unit increment doses Disposable Insulin Pens Sanofi Aventis pen Reusable Insulin Pens Novo Nordisk Lantus SoloSTAR Similar to Flex Pens Contains 3mL (300 units) of insulin, up to 80 units per dose. 1-unit increments and can be turn forward and backward to adjust dose. NovoPen 3 NovoPen 4 Used with Penfill 3mL insulin cartridges 2 to 70 units per dose in 1 unit increments NovoPen 3 cannot be dialed backwards (have to reset back to 0) NovoPen 4 can be dialed backwards and has a larger dose viewing screen Reusable Insulin Pens Lilly Pen Reusable Insulin Pens Novo Nordisk HumaPen Memoir Only for use with Humalog and uses 3mL Cartridges (100IU/mL) Up to 60 units per dose and can be dialed forward or backward for adjusting dose. 1 unit increment doses Remembers last 16 doses NovoPen Junior Used with Penfill 3mL insulin cartridges 1 to 35 units per dose in ½ unit increments Cannot be dialed backwards (have to reset back to 0)
9 Reusable Insulin Pens Opticlik Pen Lantus and Apidra Uses 3mL Lantus or Apidra cartridges Up to 80 units per dose in 1 unit increments Structurally different Pen Needles BD Pen Needles Make sure to use a new needle each time Prime the pen Do not store your pen with the needle attached Do not push the injection button until the needle is attached Other Insulin Delivery Systems Novo Nordisk InnoLet Key Features Prefilled with 3 ml (300 units) of Novolin insulin Disposable and easy to read Up to 50 units per dose in 1 unit increments Pen Needles BD Ultra-Fine Mini Pen Needle may be used for: Patients who want the shortest pen needle available in the U.S. Patients who have needle phobia Children; very thin or muscular people Patients who don t' want to pinch-up Patients who use Exenatide BD Ultra-Fine Short Pen Needle may be used for: Most patients - it's a size that is appropriate for many people Patients who want a thinner 8mm needle* Patients who use OptiClik pen for Lantus and Apidra insulins Other Delivery Pen Lilly Pen Key Features Byetta- incretin hormone 5mcg and 10mcg Contains 60 doses for 30 days of BID dosing Similar to other Lilly pens
10 Medication/Device Selection and Education Which medication is best suited for a patient? Will patients take the medications they are prescribed? What concerns do the patients have about their diabetes regimen? Which blood glucose meter will best meet the patient s needs? Which insulin delivery system will best meet the patient s needs?
Understanding Diabetes and Insulin Delivery Systems
Page 1 This program has been supported by an educational grant from Sanofi Aventis Scott K. Stolte, Pharm.D. Associate Dean, Academic Affairs Bernard J. Dunn School of Pharmacy Shenandoah University Winchester,
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationCE on SUNDAY Newark, NJ October 18, 2009
CE on SUNDAY Newark, NJ October 18, 2009 Date: Sunday, October 18, 2009 Time: 2:45 PM 3:45 PM Location: Sheraton Newark Airport Hotel Title: Speaker(s): Addressing Challenges in Type 2 Diabetes ACPE #
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationHow to Fight Diabetes and Win. Diabetes. Medications
How to Fight Diabetes and Win Diabetes Medications MEDICATIONS FOR DIABETES According to the American Diabetes Association, 85% of adults diagnosed with diabetes take insulin and/or oral medication to
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationOral and Injectable Medication Options for Diabetes Treatment
Oral and Injectable Medication Options for Diabetes Treatment Presented by: Dr. Daphne E. Smith, Pharm.D., CDE Clinical Assistant Professor/Clinical Pharmacist-University of Illinois at Chicago College
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationObjectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationHow they work and when to take them. Diabetes Medications
How they work and when to take them Diabetes Medications BIGUANIDES Metformin Actions Slows down the release of glucose from the liver. Helps the bodies cells become more sensitive to insulin. Pros Weight
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix
Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationType II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS
Type II Diabetes Improving Blood Sugar Control Geneva Clark Briggs, Pharm.D., BCPS Overview Importance of glucose control State of control Review available therapies Helping patients achieve control The
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More informationDiabetes Management: A diagnostic perspective
Diabetes Management: A diagnostic perspective Images: http://www.engadget.com/2009/09/23/bayer-introduces-countour-usb-glucose-meter/ http://www.medtronicdiabetes.com/treatment-and-products/minimed-530g-diabetes-system-with-enlite
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationFaculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives
Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationObjectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment
Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationIt is estimated that approximately 20.8 million Americans
FORMULARY MANAGEMENT Managed Care Perspective on Three New Agents for Type 2 Diabetes Shawna VanDeKoppel, PharmD; Hae Mi Choe, PharmD, CDE; and Burgunda V. Sweet, PharmD, FASHP ABSTRACT BACKGROUND: Despite
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationCURRENT STATEGIES IN DIABETES MELLITUS DIABETES. Recommendations for Adults CURRENT STRATEGIES IN DIABETES MELLITUS. Diabetes Mellitus: U.S.
CURRENT STATEGIES IN DIABETES MELLITUS Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Diabetes Mellitus: U.S. Impact ~1 Million Type 1 DIABETES 16.7 Million IFG (8.3%) 12.3
More informationInsulin Basic facts. Patient Education Patient Care Services. What is insulin? What types of insulin are there? Basal Insulin
Patient Education Insulin Basic facts Insulin is a protein made by the pancreas that allows your cells to use glucose for energy. There are different types of insulin: Basal long-acting insulin that controls
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationDisclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2
Therapy For Diabetes Michigan Association of Osteopathic Family Physicians Mid-Winter Family Medicine Update Shanty Creek Resort, MI January 19-22nd 2017 Michael R. Brennan D.O., M.S., F.A.C.E Director
More informationDrug Use Criteria: Exogenous Insulin Products
Texas Vendor Program Use Criteria: Exogenous Products Publication History 1. Developed June 2017. Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be
More informationPharmacology. Kacy Aderhold, MSN, APRN-CNS, CMSRN
Pharmacology Kacy Aderhold, MSN, APRN-CNS, CMSRN Biguanides Decreases hepatic glucose production and improves insulin sensitivity (increases number of insulin receptors) Common Adverse Reaction: diarrhea
More informationINSULIN OVERVIEW. Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro min. 3-5 hrs min.
INSULIN OVERVIEW Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro Humalog 15-30 min 30-90 min 3-5 hrs aspart glulisine Short-Acting Regular insulin NovoLog Apidra
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More information第十五章. Diabetes Mellitus
Diabetes-1/9 第十五章 Diabetes Mellitus 陳曉蓮醫師 2/9 - Diabetes 羅東博愛醫院 Management of Diabetes mellitus A. DEFINITION OF DIABETES MELLITUS Diabetes Mellitus is characterized by chronic hyperglycemia with disturbances
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationPancreatic b-cell Dysfunction in Type 2 Diabetes ZIAD KAHWASH, M.D. Insulin resistance: Defects in Insulin Signaling
Plasma insulin (mu/ml) ZIAD KAHWASH, M.D. resistance: Defects in Signaling Increased glucose production Glucose Insufficient glucose disposal X Liver glucagon insulin Pancreas Peripheral tissues (skeletal
More informationDiabetes mellitus. Treatment
Diabetes mellitus Treatment Recommended glycemic targets for the clinical management of diabetes(ada) Fasting glycemia: 80-110 mg/dl Postprandial : 100-145 mg/dl HbA1c: < 6,5 % Total cholesterol: < 200
More informationI. General Considerations
1 2 3 I. General Considerations A. Type I ( Juvenile Onset or IDDM) IDDM results from autoimmune destruction of beta cells inability to secrete insulin --> ketone formation --> DKA 4 Diabetic Ketoacidosis
More informationMaking Sense of Mediations for Diabetes
Making Sense of Mediations for Diabetes Lisa Kroon, PharmD, CDE Professor of Clinical Pharmacy UCSF School of Pharmacy Diabetes Mellitus: U.S. Impact Source: ADA; released June 10, 2014 ~1-1.5 Million
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More informationObjectives. Type 2 Diabetes: Treating an Epidemic. Angela R. Newsome, Pharm.D Mission Hospitals/MAHEC Asheville, NC April 20, 2006
Type 2 Diabetes: Treating an Epidemic Angela R. Newsome, Pharm.D Mission Hospitals/MAHEC Asheville, NC April 20, 2006 Objectives Discuss the health and economic burden of diabetes Discuss necessary lifestyle
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationThe Diabetes Guidelines Trek: The Next Generation. Inpatient Diabetes Guidelines. Learning Objectives. Current Inpatient Guidelines
The Diabetes Guidelines Trek: The Next Generation J. Christopher Lynch, PharmD, BCACP Southern Illinois University Edwardsville School of Pharmacy Susan Cornell BS, PharmD, CDE, FAPhA, FAADE Midwestern
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationA New Therapeutic Strategey for Type II Diabetes: Update 2008
Live, One Hour Webinar A New Therapeutic Strategey for Type II Diabetes: Update 2008 Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy in Grundy, Virginia.
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationRhonda Eustice, PharmD, CDE. Will Power lasts about two weeks and is soluble in alcohol. Mark Twain
Rhonda Eustice, PharmD, CDE Will Power lasts about two weeks and is soluble in alcohol. Mark Twain Diabetes Management: The Three Legged Stool Diet Medication Exercise Objectives Know the treatment goals
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationIndiana Medicaid Drug Utilization Review Board Newsletter
Indiana Medicaid Drug Utilization Review Board Newsletter Indiana Medicaid DUR Board Room W382 Indiana State Government Center, South Introduction The Management of Type 2 Diabetes Deborah K. Brokaw, Pharm.D.,
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationDiabetes in Pregnancy
Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the
More informationPharmacologic Agents for Treatment of Type 2 Diabetes
Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationType. Diabetes Drugs. A Review
Type Diabetes is a common diagnosis for home care patients. Diabetes drugs are now available that target the multiple defects of metabolism that characterize Type 2 diabetes. Understanding the wide variety
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationDiabetes Meds Update Disclaimer and Important Info. Objectives. Page 1. Copyright , Diabetes Education Services
Diabetes Meds Update 2016 Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Disclaimer and Important Info This content is for educational purposes only. Please see Package
More informationType I Type II Insulin Resistance
Insulin An aqueous hormonal solution made in the pancreas. Affects metabolism by allowing glucose to leave the blood and enter the body cells, preventing hyperglycemia. It is measured in units, e.g. 100
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationInpatient Glycemic Management:
Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures: Dr. Seley attended Advisory Board Meeting: Alliance (Boehringer-Ingelheim/Lilly) Bayer Diabetes Care Sanofi
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationAdlyxin. (lixisenatide) New Product Slideshow
Adlyxin (lixisenatide) New Product Slideshow Introduction Brand name: Adlyxin Generic name: Lixisenatide Pharmacological class: Glucagon-like peptide-1 (GLP-1) receptor agonist Strength and Formulation:
More informationRebecca Newberry APRN MS CDE
Current Diabetes Medications Nursing Implications and Applications Rebecca Newberry APRN MS CDE Methodist Center for Diabetes and Nutritional Health Disclosures Objectives Speakers Bureaus/Consulting Board
More informationMore Diabetes Potpourri : Additional Current Issues Related to Diabetes
Page 1 Scott K. Stolte, Pharm.D. Associate Dean for Academic Affairs Bernard J. Dunn School of Pharmacy Shenandoah University This program has been brought to you by PharmCon Accreditation: Pharmacists:
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationGLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018
GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018 SOMETHING TO CONSIDER IF YOU COULD PRESCRIBE A MEDICATION FOR YOUR PATIENT WITH DIABETES THAT: DECREASED
More informationAntidiabetic Agents CHAPTER BIGUANIDES
ajt/shutterstock, Inc. CHAPTER 2 Antidiabetic Agents Charles Ruchalski, PharmD, BCPS BIGUANIDES For newly diagnosed patients with type 2 diabetes, the biguanide metformin is the drug of choice for initial
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationA Fact Sheet for Parents and Carers Insulin and Diabetes
A Fact Sheet for Parents and Carers Insulin and Diabetes In type 1 diabetes the body stops producing insulin. Insulin therapy is essential in the treatment of type 1 diabetes, together with a healthy eating
More informationInitiating Injectables in Type 2 Diabetes. Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital
Initiating Injectables in Type 2 Diabetes Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital Increasing levels in delivery of diabetes care Complex Care support 3 3.1 People with diabetes
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More information